Atai Life Sciences B.V. Stock Price, News & Analysis

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health disorder treatments, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, MA. The event will take place from March 3-5, 2025.

The company's management team will engage in a fireside chat scheduled for Monday, March 3 at 11:50 A.M. ET, along with one-on-one investor meetings. A webcast of the presentation will be available, with an archived replay accessible on the Investors section of atai's website under Events for up to 90 days.

atai Life Sciences (NASDAQ: ATAI) has successfully completed its public offering of 26,190,477 common shares on February 14, 2025, followed by the underwriter's full exercise of its option to purchase an additional 3,928,571 shares at $2.10 per share on February 17, 2025. The total gross proceeds amounted to approximately $63.25 million.

The company plans to use the net proceeds for general corporate purposes, including working capital and advancing clinical development of its product candidates. Based on the planned use of proceeds and current operating plan, atai projects that its existing cash, short-term securities, public equity holdings, and committed term loan facility will fund operations into 2027. Berenberg acted as the sole bookrunner for the offering.

atai Life Sciences (NASDAQ: ATAI) has announced the pricing of a registered underwritten public offering of 26,190,477 common shares at $2.10 per share. The company expects to raise approximately $55 million in gross proceeds before deducting underwriting costs and other expenses.

The offering includes a 30-day option for the underwriter to purchase up to an additional 3,928,571 common shares. Berenberg is serving as the sole bookrunner for the offering, which is expected to close on February 14, 2025. The proceeds will be used for general corporate purposes, including working capital and advancing clinical development of product candidates and programs.

The offering is being made through an effective shelf registration statement filed with the SEC on July 1, 2022, and declared effective on July 11, 2022.

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health disorder treatments, has announced a proposed registered underwritten public offering of $55 million in common shares. The company will grant underwriters a 30-day option to purchase up to an additional $8.25 million of common shares.

Berenberg is serving as the sole bookrunner for the offering. The proceeds will be used for general corporate purposes, including working capital and advancing clinical development of product candidates and programs. The offering is being made through an effective shelf registration statement filed with the SEC on July 1, 2022.

atai Life Sciences (NASDAQ: ATAI) announced positive topline results from Beckley Psytech's Phase 2a open-label study of BPL-003, a synthetic intranasal formulation of 5-MeO-DMT benzoate, in treating alcohol use disorder (AUD). The study, involving 12 patients with moderate to severe AUD, demonstrated significant improvements following a single dose combined with relapse prevention therapy:

Key results after 12 weeks include:

• Reduction in daily alcohol consumption from 9.3 to 2.2 units
• Decrease in heavy drinking days from 56% to 13%
• Increase in abstinent days from 33% to 81%
• 50% of patients maintained complete abstinence

The treatment was well-tolerated with only mild to moderate adverse events reported, and patients were typically ready for discharge within two hours. Beckley Psytech plans to evaluate future development options and share additional clinical data throughout 2025.

atai Life Sciences (NASDAQ: ATAI) has announced significant leadership changes to advance its pipeline of mental health therapeutics. Srinivas Rao, M.D., Ph.D., has become the sole Chief Executive Officer, while Kevin Craig, M.D. has been promoted to Chief Medical Officer, Glenn Short, Ph.D. to Chief Scientific Officer, and Gerd Kochendoerfer, Ph.D. has joined as Chief Operating Officer.

The company is at a important phase with VLS-01 and EMP-01 advancing into Phase 2 clinical trials. VLS-01 is currently screening patients, and the company anticipates mid-year Phase 2b data readout for Beckley Psytech's BPL-003, marking a significant step toward developing commercially scalable short-duration psychedelic therapies for treatment-resistant depression.

Each new leader brings substantial expertise: Dr. Craig has over 20 years of clinical experience, Dr. Short possesses more than 20 years of industry experience, and Dr. Kochendoerfer contributes 25+ years of pharmaceutical and biotech leadership experience.

atai Life Sciences (NASDAQ: ATAI) reported Q3 2024 financial results and pipeline updates. The FDA cleared the IND for VLS-01 (buccal film DMT) for treatment-resistant depression, with Phase 2 study initiation expected around YE'24. The company plans to initiate Phase 2 study of EMP-01 (oral R-MDMA) for social anxiety disorder around YE'24. Q3 net loss was $26.3M, with cash position at $101.0M. R&D expenses were $12.4M, down from $13.3M year-over-year, while G&A expenses decreased to $10.3M from $13.6M. The company expects current funding to support operations into 2026.

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on transforming mental health disorder treatments, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event is scheduled from October 15 – 17, 2024.

Key details of atai's involvement include:

• Participant: Srinivas Rao, M.D., Ph.D., Co-founder and Co-CEO
• Format: Virtual fireside chat
• Date: Wednesday, October 16, 2024
• Presentation Time: 3:30 P.M. EDT

A webcast registration link is provided, and an archived replay will be available on the Investors section of atai's website under Events for up to 30 days after the presentation.

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health disorders, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. The company's management team will engage in a fireside chat on Tuesday, September 10 at 4:30 P.M. EDT, along with 1x1 investor meetings.

Investors can access the fireside chat via a provided webcast link, and an archived replay will be available on the company's website for up to 90 days. This participation offers atai an opportunity to showcase its progress and strategies in transforming mental health treatment to a global investment audience.